| scholarly article | Q13442814 |
| P50 | author | Bruce Ernest Kemp | Q21165436 |
| P2093 | author name string | Zhiping Chen | |
| Alan Kozikowski | |||
| Melinda Hollingshead | |||
| Joell J Gills | |||
| Phillip A Dennis | |||
| Regan M Memmott | |||
| Margaret C Powers | |||
| P2860 | cites work | Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade | Q21245891 |
| The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress | Q24633606 | ||
| TSC2 mediates cellular energy response to control cell growth and survival | Q27860970 | ||
| A serine/threonine kinase gene defective in Peutz-Jeghers syndrome | Q28119198 | ||
| TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling | Q28131740 | ||
| Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung | Q28208680 | ||
| An expanding role for mTOR in cancer | Q28260391 | ||
| The LKB1 tumor suppressor negatively regulates mTOR signaling | Q28272728 | ||
| Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase | Q28567006 | ||
| The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin | Q28590162 | ||
| LKB1 is the upstream kinase in the AMP-activated protein kinase cascade | Q28610414 | ||
| Patterns of somatic mutation in human cancer genomes | Q29547841 | ||
| Cancer statistics, 2006 | Q29615133 | ||
| A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia | Q29615437 | ||
| AMP-activated protein kinase induces a p53-dependent metabolic checkpoint | Q29618123 | ||
| LKB1 modulates lung cancer differentiation and metastasis | Q30080027 | ||
| STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase | Q31040218 | ||
| Management of cellular energy by the AMP-activated protein kinase system | Q34209246 | ||
| Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. | Q34438345 | ||
| Mammalian TOR: a homeostatic ATP sensor | Q34519173 | ||
| 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments | Q35070875 | ||
| Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. | Q36301403 | ||
| Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome | Q38312576 | ||
| Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms. | Q40107095 | ||
| LKB1 mutation in large cell carcinoma of the lung | Q40258656 | ||
| Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. | Q40302588 | ||
| The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases | Q40404608 | ||
| Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues | Q40566229 | ||
| Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade | Q42160057 | ||
| Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. | Q44293983 | ||
| A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway | Q44297061 | ||
| LKB1 protein expression in the evolution of glandular neoplasia of the lung. | Q44369413 | ||
| The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia | Q62746091 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 580-588 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells | |
| P478 | volume | 68 |
| Q36207311 | AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. |
| Q36917074 | Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents |
| Q37114404 | Akt-dependent and -independent mechanisms of mTOR regulation in cancer |
| Q30523059 | Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine |
| Q37584587 | Common risk variants for colorectal cancer: an evaluation of associations with age at cancer onset |
| Q28083964 | Evidence of cancer-promoting roles for AMPK and related kinases |
| Q35095146 | Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells |
| Q39366426 | Extreme Depletion of PIP3 Accompanies the Increased Life Span and Stress Tolerance of PI3K-null C. elegans Mutants |
| Q37383513 | LKB1 and AMP-activated protein kinase control of mTOR signalling and growth |
| Q37850361 | LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor |
| Q37811822 | LKB1 regulated pathways in lung cancer invasion and metastasis |
| Q37333592 | LKB1; linking cell structure and tumor suppression |
| Q39546982 | Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: evidence for a combined use with 3-bromopyruvate i |
| Q35333423 | Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis |
| Q33882138 | Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain |
| Q35793735 | RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer |
| Q37642294 | Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. |
| Q38214338 | Sex and gender influences on pharmacological response: an overview |
| Q35042551 | Susceptibility to ATP depletion of primary proximal tubular cell cultures derived from mice lacking either the α1 or the α2 isoform of the catalytic domain of AMPK. |
| Q37730668 | Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin |
| Q35781311 | Targeting AMPK for cancer prevention and treatment |
| Q37011502 | Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy |
| Q33493174 | Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia |
| Q29617506 | The LKB1-AMPK pathway: metabolism and growth control in tumour suppression |
| Q36453693 | The effect of metformin and thiazolidinedione use on lung cancer in diabetics |
| Q37868445 | The role of LKB1 in lung cancer |
| Q55435308 | [Progress of related targets in LKB1 signaling pathway for non-small cell lung cancer therapy]. |
Search more.